CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 23,250 enrolled
Drug / intervention
Non-immunogenic staphylokinasedrug
Likely dose
Non-immunogenic staphylokinase 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06707987
NCT06707987N/ACompleted
CompareCT.gov

An Open, Prospective, Non-interventional, Multicentre, Controlled Study of Safety and Efficacy of the Thrombolysis With the Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke (FORPI Registry)

Supergene, LLC·observational·Posted Nov 27, 2024·Updated Dec 5, 2025

In Brief

An observational study evaluating Non-immunogenic staphylokinase for Acute Ischemic Stroke. Completed, enrolled 23,250 participants across 1 site.

Detailed Summary

The aim of FORPI Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with acute ischemic stroke in routine clinical practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Ischemic Stroke
CountriesRussia
CollaboratorsFederal Center of Cerebrovascular Pathology and Stroke, Russian Federation Ministry of Health

Timeline

N/ACompletedFinished
20222023202420252026
First PostedNov 27, 2024
Enrollment StartMar 1, 2021
Primary CompletionDec 31, 2024
Study CompletionFeb 1, 2025
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 1.6 years ago

Interventions

Non-immunogenic staphylokinasedrug

Drug: non-immunogenic staphylokinase 10 mg as a single intravenous bolus Other Names: Fortelyzin®